DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20214786

Expression of AgNOR in histopathologically diagnosed gastric carcinoma patients

Thanadar Ajmiree Flora, Enamul Kabir, Shahnaj Begum, Rizwana Rahman Khan, Tania Gaffar, Thanadar Tamjeeda Tapu

Abstract


Background: Worldwide, gastric cancer is the second leading cause of cancer-related fatalities, after lung cancer. Identifying stomach cancer without relying entirely on histopathology is critical. The Silver-stained nucleolar organizer regions (AgNOR's) reflect the aggressiveness of the tumor, according to the study. To establish the effectiveness of these approaches in detecting stomach cancer, the present study was done in order to test their efficacy. The aim of the study was to observe expression of AgNOR in histopathologically diagnosed gastric carcinoma patients.

Methods: This cross-sectional analytical study was carried out in the department of pathology, Sir Salimullah Medical College, Dhaka, Bangladesh from July 2017 to June 2019. A total of 60 adults who were histopathologically diagnosed patients with gastric carcinoma in gastric endoscopic biopsies and resected samples.

Results: More than one-third of the patients (38.3%) belonged to the age group of 61-70 years. The age range of the participants was 40-82. 55% were male and 45% were female, 63.3% of the cancers were in the pylorus region, 33.3% were in the body and 3.3% were in the cardiac end. 80% of the GC were intestinal type and 20% were of diffuse type. 50% of the cancers were moderately differentiated, 36.67% were poorly differentiated, and 13.33% were well differentiated. The association between histopathological grading of gastric carcinoma and AgNOR was statistically significant.

Conclusions: The growth of the tumor is highly variable. The AgNOR stain is also a good marker to detect the proliferation of tumor cells.


Keywords


Expression, AgNOR, Histopathology, Gastric carcinoma

Full Text:

PDF

References


Haenszel W. Variation in incidence of and mortality from stomach cancer, with particular reference to the United States. J Natl Cancer Inst. 1958;21(2):213-62.

Coleman MP, Estève J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC Sci. 1993;(121):1-806.

Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013;8:76.

Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607-15.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.

Alpízar W, Nielsen BS, Sierra R, Illemann M, Ramírez JA, Arias A, et al. Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries. Int J Cancer. 2010;126(2):405-15.

Jeung J, Patel R, Vila L, Wakefield D, Liu C. Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis. Arch Pathol Lab Med. 2012;136(6):610-7.

Crocker J, Nar P. Nucleolar organizer regions in lymphomas. J Pathol. 1987;151(2):111-8.

Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107(3):230-6.

Macdonald JS. Gastric cancer--new therapeutic options. N Engl J Med. 2006;355(1):76-7.

Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241(1):27-39.

Lee GH, Joo YE, Koh YS, Chung IJ, Park YK, Lee JH, et al. Expression of survivin in gastric cancer and its relationship with tumor angiogenesis. Eur J Gastroenterol Hepatol. 2006;18(9):957-63.

Sanaat Z, Halimi M, Ghojezadeh M, Pirovi AH, Gharamaleki JV, Ziae AE, et al. Immunohistochemical Analysis of p53, Ki-67, CD44, HER-2/neu Expression Patterns in Gastric Cancer, and Their Association with One Year Survival in North-West of Iran. Int J Hematol Oncol Stem Cell Res. 2013;7(3):15-20.

Tiwari E, Pallipady A, Misra R, Mishra S. P53 and Ki67 immunostaining in gastric biopsies: A histopathological study. Int J Sci Stud. 2015;2(11):96-101.

Shafigh E, Abdolazimi Y, Shafaie SHM. Expression of biomarkers Ki-67, p27KIP1, p53 in gastric cancer andtheir association with histopathologic indicators of gastrectomy samples of patients reffered to Shahid Beheshti hospital Babol Iran in 2000-2006. Univ Med Scienc Babol. 2007;9(4):7.

Gosh S, Ghosh TK, Dewasi N, Das K. Prognostic information of gastric carcinoma using Goseki system in relation to nuclear organizer region (AgNOR) and proliferating cell nuclear antigen (PCNA) expression. Bangladesh J Med Sci. 2010;9(2):76-86.